Navigation Links
Uroplasty Reports Financial Results for the Third Quarter FY2011
Date:1/27/2011

MINNEAPOLIS, Jan. 27, 2011 /PRNewswire/ -- Uroplasty, Inc. (Nasdaq: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported financial results for the third fiscal quarter ended December 31, 2010.

Global sales grew 14% to $3.5 million, compared with $3.1 million in the same quarter a year ago.  The growth was driven by strength in U.S. sales, up 33% from the third quarter a year ago.  The increase in U.S. sales reflected a 64% increase in sales of the Macroplastique product line, where the Company has had a focused marketing effort. Sales of the Urgent PC Neuromodulation System in the U.S. for the recent third fiscal quarter totaled $1.0 million, an increase of 10% from the prior year's third quarter.  The number of customers in the U.S. purchasing the Urgent PC Neuromodulation System during the quarter increased to 236 from 185 in the second quarter ended September 30, 2010.

The Company also announced that two additional Medicare carriers, Cahaba Government Benefit Administrators®, LLC and First Coast Service Options, Inc. (FCSO), have begun to pay for Percutaneous Tibial Nerve Stimulation (PTNS) treatments, using the Urgent PC Neuromodulation System. Cahaba administers Medicare health insurance for the states of Alabama, Georgia, Mississippi and Tennessee. FCSO is the Medicare carrier for Florida, Puerto Rico and the U.S. Virgin Islands.

With the addition of these two carriers, there are now nine regional Medicare carriers providing coverage for PTNS, using Urgent PC, for the treatment of symptoms of overactive bladder syndrome in 29 states and two territories.  Coverage of PTNS using the Urgent PC Neuromodulation System, currently extends to approximately 28 million lives of the 46 million total lives covered under Medicare.

"We were ver
'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Uroplasty to Issue Third Quarter 2011 Results on January 27, 2011
2. Uroplasty Announces Addition of Robert Kill to its Board of Directors
3. Additional Regional Medicare Carrier Initiates Coverage for Posterior Tibial Nerve Stimulation (PTNS) Delivered via Uroplastys Urgent® PC Neuromodulation System
4. Uroplasty Inc. Announces CPT® Category I Code and Associated Reimbursement Value for Posterior Tibial Nerve Stimulation
5. Uroplasty Reports Financial Results for the Second Quarter FY2011
6. Uroplasty to Issue Second Quarter 2011 Results on October 27, 2010
7. Uroplasty to Present at The 5th Annual JMP Securities Healthcare Conference
8. Coverage Initiated by Two Regional Medicare Carriers for Posterior Tibial Nerve Stimulation (PTNS) Delivered Via Uroplastys Urgent® PC Neuromodulation System
9. Uroplasty to Present at Global Hunter Securities Inaugural Healthcare Conference
10. Uroplasty Reports Results for Second Quarter FY2010
11. Uroplasty to Issue Second Fiscal Quarter Results on November 2, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- CAS Medical Systems, Inc. (NASDAQ: CASM ) (CASMED), ... announced that Thomas M. Patton , President ... Annual Marcum MicroCap Conference on Thursday, May 30, 2013, ... City . The presentation is scheduled to ... and will be available via a live webcast at ...
(Date:5/23/2013)...  Omeros Corporation (NASDAQ: OMER ) ... (IND) to evaluate OMS824 in Huntington,s disease has ... Administration (FDA). OMS824 selectively inhibits phosphodiesterase 10 (PDE10), ... linked to a wide range of diseases that ... has shown promising results in animal models directly ...
(Date:5/23/2013)... , May 23, 2013  Echo Pharma Acquisition Limited ... waive down the Acceptance Threshold from 90 percent to ... Elan Share in accordance with the terms of the ... summarized below. Under the terms of the ... (NYSE: ELN ) for $12.50 per share ...
Breaking Medicine Technology:CASMED to Present at the 2nd Annual Marcum MicroCap Conference 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 2Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 3Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 5Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 6Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 7Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 8Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 9Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 10
(Date:5/23/2013)... 23 (HealthDay News) -- A shortage of a critical ... across the United States to contain the spread of ... The drug, isoniazid (INH), was first used in 1951 ... the core of any first-line treatment for tuberculosis (TB). ... months, according to the U.S. Centers for Disease Control ...
(Date:5/23/2013)... have shown that an immune regulatory molecule called IL-21 ... viral infections. , The results are published in the ... how IL-21 could be important in the development of ... PhD, the first author of the paper. The senior ... Vaccine Center and a Georgia Research Alliance Eminent Scholar. ...
(Date:5/23/2013)... 2013 Netsmart today announced it ... of healthcare information technology (HIT) providers for 2013. , The ... of Healthcare Informatics magazine. Netsmart’s ranking of #49 ... strong continued growth is largely due to our commitment to ... of healthcare where resources are scarce, the demand for care ...
(Date:5/23/2013)... researchers examining outcomes for advanced heart-failure patients over ... with the increased availability and use of new ... death, caused by the rapid onset of severe ... However, the team found that even today, with ... more than three years after being diagnosed with ...
(Date:5/23/2013)... Elegance for a woman takes on so many ... her intrigue can often be found in the mystery of her ... soul is through her eyes. It is also true that ... is why the elegance of a woman can be found in ... more than any other time, utilize eyewear to not only compliment ...
Breaking Medicine News(10 mins):Health News:Shortage of Key Drug Hampering U.S. Efforts to Control TB: Report 2Health News:Vaccine blackjack: IL-21 critical to fight against viral infections 2Health News:Netsmart Named to Healthcare Informatics Top 100 List 2Health News:Death rates decline for advanced heart failure patients, but outcomes are still not ideal 2Health News:Death rates decline for advanced heart failure patients, but outcomes are still not ideal 3Health News:Dolabany Eyewear Adds Feminine Flare to Women's Designer Eyewear with 2013 New Release of Adelina by Best Image Optical, Inc. 2
... James S. Forrester, M.D., former chief of the ... the 2009 Lifetime Achievement Award from the American College ... March 29. , Currently the George Burns ... Forrester came to the medical center in 1969 as ...
... These new insights represent an important contribution to future ... prestigious science journal Nature and will be ... molecular mechanisms of hematopoiesis, which will take place in ... findings on the molecular mechanisms of blood formation (hematopoiesis) ...
... Overestimate Amount of Time it Takes to Form a New ... to Achieving Healthier HabitsGREENWICH, Conn., April 1 ... Nestle(R) Pure Life (R) brand bottled water, the number one ... think it takes six months or longer to form a ...
... PALM BEACH GARDENS, Fla., April 1 As ... http://www.silvercensus.com ), a national web ... announced today that it is urging American Veterans ... entitlement from the Veterans Administration called "Aid and ...
... Mass., April 1, EnVivo Pharmaceuticals today ... Corporation (MTPC) for the development and commercialization ... Japan and several other Asian countries. EVP-6124 ... agonist currently in development for cognition enhancement ...
... April 1 Immunotech Laboratories, Inc. Immunotech Laboratories ... in Puerto Rico with its abstract " Irreversible ... specific novel cytokine stimulation in vitro investigation of ... at the 5th European Conference on Clinical and ...
Cached Medicine News:Health News:ACC presents lifetime achievement award to Cedars-Sinai Heart Institute's James Forrester, M.D. 2Health News:Last step leading to blood cell formation elucidated 2Health News:Video: New Survey Reveals Misconceptions About Forming New Habits 2Health News:Video: New Survey Reveals Misconceptions About Forming New Habits 3Health News:Video: New Survey Reveals Misconceptions About Forming New Habits 4Health News:Little-Known VA Care Entitlement for Veterans Highlighted by SilverCensus.com 2Health News:Little-Known VA Care Entitlement for Veterans Highlighted by SilverCensus.com 3Health News:EnVivo and Mitsubishi Tanabe Enter License Agreement on EVP-6124 in Japan, Korea, Taiwan and Other Asian Countries 2Health News:EnVivo and Mitsubishi Tanabe Enter License Agreement on EVP-6124 in Japan, Korea, Taiwan and Other Asian Countries 3Health News:Beating a Global Killer: HIV/AIDS 2Health News:Beating a Global Killer: HIV/AIDS 3Health News:Beating a Global Killer: HIV/AIDS 4
...
The Doro Halo retractor system is designed for all neurosurgical applications where retraction of the brain tissue and an armrest is required....
Codman periosteal elevators, sharp, length 8" (203 mm), blade width 3/16" (5 mm)....
Hoen periosteal elevators, No.3, blade width 3/4" (20 mm), total length 7 1/2" (191 mm)....
Medicine Products: